Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.
about
The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis.The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migrationThe complex interplay between ERK1/2, TGFβ/Smad, and Jagged/Notch signaling pathways in the regulation of epithelial-mesenchymal transition in retinal pigment epithelium cells.Fasudil, a Clinically Used ROCK Inhibitor, Stabilizes Rod Photoreceptor Synapses after Retinal DetachmentAlterations in the intraocular cytokine milieu after intravitreal bevacizumab.High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusionComparison of gene expression profile of epiretinal membranes obtained from eyes with proliferative vitreoretinopathy to that of secondary epiretinal membranesTGF-β2 reduces nitric oxide synthase mRNA through a ROCK-dependent pathway in airway epithelial cells.Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β1,6-N-Glycosylation and Increased Susceptibility to Galectin-3 Binding.Upregulation of Mir-21 Levels in the Vitreous Humor Is Associated with Development of Proliferative Vitreoretinal Disease.Bone structural components regulating sites of tumor metastasisVitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathyRho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.RhoA Signaling and Synaptic Damage Occur Within Hours in a Live Pig Model of CNS Injury, Retinal Detachment.Inhibitory Effect of Bone Morphogenetic Protein 4 in Retinal Pigment Epithelial-Mesenchymal TransitionPirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro.Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis.Resveratrol inhibits transforming growth factor-β2-induced epithelial-to-mesenchymal transition in human retinal pigment epithelial cells by suppressing the Smad pathway.Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in miceA retrospective study comparing outcomes of primary rhegmatogenous retinal detachment repair by scleral buckling and pars plana vitrectomy in Finland.Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells.Long-term diabetic complications may be ameliorated by targeting Rho kinase.Disease pathways in proliferative vitreoretinopathy: an ongoing challenge.Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study.From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathyThe roles of signaling pathways in epithelial-to-mesenchymal transition of PVR.RNA Interference Targeting Snail Inhibits the Transforming Growth Factor β 2-Induced Epithelial-Mesenchymal Transition in Human Lens Epithelial Cells.Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.Trichostatin A Inhibits Retinal Pigmented Epithelium Activation in an In Vitro Model of Proliferative Vitreoretinopathy.The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-β2 in human retinal pigment epithelial cells.Suppressive effect of AMP-activated protein kinase on the epithelial-mesenchymal transition in retinal pigment epithelial cells.ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.ROCK as a Therapeutic Target of Diabetic RetinopathyA selective inhibitor of the Rho kinase pathway, Y-27632, and its influence on wound healing in the corneal stroma.Regulation of Na,K-ATPase β1-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells.Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levelsCell-mediated contraction of vitreous explants from chicken embryo: possibility of screening for therapeutic agents against proliferative vitreoretinal diseases.Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.Upregulation of TGF-ß1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition.Periostin in vitreoretinal diseases.
P2860
Q24299587-3746209E-FC31-4185-83F5-364446089CBAQ30436035-3339211E-BADF-4F1E-A36E-E040FCF4562FQ33560424-BC00BDA7-6F91-4C4D-878C-CD3822AAFBE6Q33828265-614894F8-6B1D-466D-814F-D3741CAEE1AFQ33845524-8CB71E3A-8D4F-4BC9-87E2-69021D850DBDQ34200359-AC82F361-D33C-4DE5-9FBB-C189FCADDF07Q34571014-B2ECB667-27D4-437F-A007-8143842E171CQ34630384-67F6B434-2233-4F0F-84B8-6B9B216C5CCCQ35892475-E223189C-1892-42BB-9A5F-AC8F189F6CB2Q36063043-9613ECDD-72F7-45BA-975B-C189C1ACA856Q36196602-A9C312E1-7926-4B68-9722-EBAC9008F282Q36662676-597F6F5D-3840-4E1F-9ED8-B94C2127E9D7Q37023057-50E89D21-2FB0-40D7-BD73-9DE4A6D1E42EQ37152871-8BCD82E8-D2F5-42A0-828F-973B3FCD614FQ37227950-2D33C5D8-84B0-4403-8644-633ACE33B0E3Q37445130-C0CB5DF8-AE0B-4321-A266-EBC5C731E09AQ37524234-6027CA8D-11B4-421C-A8EA-F863EB1DF62EQ37590386-427EDA69-0774-4D9D-BFB7-32094E7450C1Q37624843-51E01E46-F8AA-4408-B475-95BD282FFF48Q37705634-3A7961A9-75CA-448F-AD7E-9FCD463E9241Q37724028-49AAE0CA-B43A-4C30-8461-2A77A74480A7Q37838899-65E69201-A7FA-4282-9FA5-03FDA453AFDDQ38194096-2D834453-FF8A-4EA8-839D-49EF66F6D6A3Q38307971-9F9796A1-7122-4EC1-A9A4-E048458A37D1Q38332124-E4922283-59A6-435E-AE8C-58DB8277F167Q38537520-922E4269-6B85-4D6B-B1B0-6E389C322613Q39069835-95F0C078-BE98-4154-8B8B-ABAB6E3F151BQ39361069-C36386A9-79A0-4584-B0B1-4B45A1D79B46Q39520301-3FF8FAD2-4E69-4780-9675-A0D0392A80FDQ40533401-F044E00E-5BA4-4A0D-A91F-3280180ACAF9Q41047846-03C93D60-6B19-46B1-9A2A-A0DB86337E64Q41458803-8505CFC1-F77C-4DC8-A2C9-5450CE15D3B7Q41873958-BEE4A705-2CF5-48AD-ADC9-38D8F37210E7Q42028653-4A155864-2F5F-4D3C-90E7-44D962F08D81Q42072283-2F3264CD-3AB5-4C29-8291-71DC7A9782B4Q42755143-065ECA0B-1A31-48BF-AC7E-AD824CA1C9D9Q42846718-1785A5CD-774E-40D1-8FEF-2BE8411A4C71Q45905920-CDF5A001-140A-4660-A702-4D5EE6DC25D8Q46702110-C36DDEA1-76D2-4215-AF7F-414E9DD8049FQ47797906-CAAC70E4-CFC0-4497-A583-92F3C115FDBB
P2860
Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Role of TGF-beta in proliferat ...... ROCK as a therapeutic target.
@en
type
label
Role of TGF-beta in proliferat ...... ROCK as a therapeutic target.
@en
prefLabel
Role of TGF-beta in proliferat ...... ROCK as a therapeutic target.
@en
P2093
P2860
P356
P1476
Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target
@en
P2093
Hiroaki Shimokawa
Hiroshi Enaida
Muneki Miura
Ryoichi Arita
Shintaro Nakao
Shuhei Kawahara
Takeshi Kita
Tatsuro Ishibashi
Yasuaki Hata
Yasutaka Mochizuki
P2860
P304
17504-17509
P356
10.1073/PNAS.0804054105
P407
P577
2008-10-24T00:00:00Z